<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01065220</url>
  </required_header>
  <id_info>
    <org_study_id>AP13214ONB</org_study_id>
    <nct_id>NCT01065220</nct_id>
  </id_info>
  <brief_title>Sex Steroids and the Serotonin Transporter</brief_title>
  <official_title>The Influence of Sex Steroid Hormones on Serotonin Transporter Binding in the Human Brain Investigated by Positron Emission Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to prove the influence of the sex steroid hormones estrogen,
      progesterone and testosterone on the serotonin transporter (5-HTT) binding using positron
      emission tomography (PET) and the selective radioligand [11C]DASB. Specifically, the 5-HTT
      binding will be quantified before and after hormone therapy underwent by 10 male-to-female
      (MtF) and 10 female-to-male (FtM) transsexuals urging for hormone treatment. The high-level,
      long-term administration of opsite sex steroid hormones in transsexuals provide the unique
      opportunity to investigate the influence of sex steroid hormones on the serotonergic system.
      Since the serotonin transporter serves as a primary target molecule for antidepressant
      treatment, the results of the study will be of benefit for the assessment of the clinical
      relevance of estrogen and testosterone as modulatory and neuroactive agents.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in serotonin-transporter binding potential (BP) in predefined brain regions, measured by Positron Emission Tomography</measure>
    <time_frame>5 months</time_frame>
    <description>The serotonin-transporter BP will be assessed in a 90 min. dynamic PET measurement session at three timepoints: before start of hormonal therapy, after four weeks of hormonal therapy, and after 4 months of hormonal therapy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Transsexualism</condition>
  <arm_group>
    <arm_group_label>hormone treatment for MtF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cyproterone acetate
estradiol
alpha-5-reductase-inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hormone treatment for FtM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>testosterone undecanoate
lynestrenol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testolactone undecanoate</intervention_name>
    <description>4ml i.m.</description>
    <arm_group_label>hormone treatment for FtM</arm_group_label>
    <other_name>Nebido®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lynestrenol</intervention_name>
    <description>2/day</description>
    <arm_group_label>hormone treatment for FtM</arm_group_label>
    <other_name>Orgametril®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyproterone Acetate</intervention_name>
    <description>50mg per day</description>
    <arm_group_label>hormone treatment for MtF</arm_group_label>
    <other_name>Androcur®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol</intervention_name>
    <description>100 microgram TTS twice a week</description>
    <arm_group_label>hormone treatment for MtF</arm_group_label>
    <other_name>Estradot®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-alpha reductase inhibitor</intervention_name>
    <description>1mg daily</description>
    <arm_group_label>hormone treatment for MtF</arm_group_label>
    <other_name>Finasterid®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  somatic health

          -  no previous sex hormone medication

          -  willingness to sign the written informed consent

        Exclusion Criteria:

          -  severe diseases

          -  steroid hormone treatment within 6 months prior inclusion

          -  treatment with psychotropic agents such as selective serotonin reuptake inhibitors
             (SSRIs)

          -  any implant or stainless steel graft

          -  positive urine pregnancy test in women at the screening visit at each PET day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rupert Lanzenberger, MD A/Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry and Psychotherapy, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2010</study_first_submitted>
  <study_first_submitted_qc>February 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2010</study_first_posted>
  <last_update_submitted>January 2, 2014</last_update_submitted>
  <last_update_submitted_qc>January 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Rupert Lanzenberger</investigator_full_name>
    <investigator_title>A/Prof. PD Dr.</investigator_title>
  </responsible_party>
  <keyword>Serotonin Transporter</keyword>
  <keyword>Hormone therapy</keyword>
  <keyword>Gender Dysphoria</keyword>
  <keyword>Transsexualism</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Cyproterone</mesh_term>
    <mesh_term>Cyproterone Acetate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Lynestrenol</mesh_term>
    <mesh_term>Serotonin</mesh_term>
    <mesh_term>Testolactone</mesh_term>
    <mesh_term>5-alpha Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

